Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
About this item
Full title
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
Author / Creator
Publisher
Springer
Journal title
PharmacoEconomics, 2018, Vol.36 (8), p.1015
Language
English
Formats
Publication information
Publisher
Springer
Subjects
More information
Scope and Contents
Contents
To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population). The model was structu...
Alternative Titles
Full title
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A714601169
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A714601169
Other Identifiers
ISSN
1170-7690
DOI
10.1007/s40273-018-0675-9
How to access this item
Log in as a Library member
